002_CoverageCalculatorPy https://github.com/AWGL/CoverageCalculatorPy



https://byteofbio.com/archives/7.html

https://byteofbio.com/archives/14.html

## 【染色体非整倍性】
早期染色体不稳定（CIN）是随机出现的，有稳定的克隆性改变（clonal chromosomal alterations. CCA）和不稳定的非克隆性改变（NCCA）两种形式 ，NCCA是结构CIN和癌症演化的主要标志。

CIN中的拷贝数变异（numerical CIN ，CNV），或称染色体非整倍性或称染色体畸变（aneuploidy）。除整条染色体拷贝数的变化外，染色体非整倍性还包括了染色体臂的扩增或缺失。需要注意，全染色体错误分离的机制与引起臂水平拷贝数变化的机制有很大不同。染色体非整倍性可通过增加遗传异质性，促进肿瘤发生。研究表明，非整倍性是一种与环境有关的、特定于癌症类型的致癌事件，可作为具有临床意义的预后指标和潜在治疗靶标。

![](pics/20200528_1.png)

## purity & ploidy 

### 拷贝数和倍性
```

Q:I ran Sequenza for one tumor sample with the matched normal control. I obtained purity 0.9 and ploidy 3 for the tumor. When I saw the chromosome plots, I found that regions showing depth ratio close to 1 were set to copy number 3. In my understanding, copy numbers for depth ratio 1 should be 2 because normal control would have diploid. Is there a relation between copy number setting and ploidy?


A:Yes, when the normalised depth ratio is equal to 1, it means that the segment have copy number equal to the ploidy sample.

It depends on the mechanism that have lead to the various rearrangements, but in a simple case, If ploidy is 3 it means that overall the chromosomes have 3 copies. In this cases you can inspect that the B-allele frequency is lower then in region with 2 or 4 copies and have a balanced number of alleles (if any AB, AABB)
```
https://www.biostars.org/p/219968/

1. The log ratio of 2 copies depends on the ploidy. Samples with ploidy > 2 have more DNA to sequence than normals.


## sub-clones 

## 等位基因不平衡
当同源染色体片段相对于另一条同源染色体的拷贝数增加或减少时,伴随着一个现象的发生,等位基因不平衡。如果被扩增的同源染色体的片段携带着比另一条同源染色体更有利于肿瘤生长的遗传变异位点,则此片段在肿瘤细胞生长过程中有选择性优势。

## Tumors are not completely diploid due to copy number aberrations, and the tumor ploidy (average copy number of the entire tumor genome) is hard to assess beforehand.


## 资源

[肿瘤分类](http://oncotree.mskcc.org/#/home)

https://www.cancerquest.org/zh-hans/geihuanzhe/aizhengzhonglei/qianliexianai
https://www.nature.com/articles/s41576-021-00338-8
https://www.gimjournal.org/article/S1098-3600(21)00974-6/fulltext


## actionable mutation
An actionable mutation is defined as a genetic aberration in a patient's tumor that is targetable with an available anticancer treatment or is the target of novel therapeutics in development.
> https://www.hoparx.org/hopa-news/volume-17-issue-2-2020/feature-actionable-mutations-in-solid-tumors
